Form 4: Cartesian Therapeutics Executive Exercises Stock Options

Emily English, Chief Operations Officer of Cartesian Therapeutics, exercised stock options to acquire 7,500 shares of common stock at $3.3 per share on May 12, 2025.

Summary

• On May 12, 2025, Emily English, the Chief Operations Officer of Cartesian Therapeutics, exercised stock options.
• This transaction involved the acquisition of 7,500 shares of common stock at a price of $3.3 per share.
• Following the transaction, English directly owns 55,226 shares of Cartesian Therapeutics.
• The exercised stock options were fully vested and exercisable on May 12, 2025.
• The options expire on April 25, 2031.
• The options were originally granted for Old Cartesian common stock and converted into options for the issuer's common stock following a merger on November 13, 2023.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The exercise of options could be seen as a positive sign of confidence, but it's a routine filing.

Positives

• The exercise of stock options by a key executive could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be used by investors to gauge sentiment.

Stakeholder Impact

• The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

stock options, Form 4, Cartesian Therapeutics, RNAC, executive compensation, beneficial ownership, Emily English